KF
NKTR icon

Krilogy Financial’s Nektar Therapeutics NKTR Stock Holding History

Krilogy Financial’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20
Closed -$18K – 482
2018
Q3 		$18K Buy
+20
New +$17.1K ﹤0.01% 445
2018
Q2 		– Sell
-27
Closed -$43K – 464
2018
Q1 		$43K Buy
+27
New +$34.8K 0.01% 345

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Krilogy Financial's NKTR Position: Q4 2018 in Review

Krilogy Financial sold out of Nektar Therapeutics (NKTR) in Q4 2018, closing a stake of 20 shares — an estimated $18K sold.

Krilogy Financial first reported a position in NKTR in Q1 2018 and held it in 2 quarters. The position peaked at $43K in Q1 2018. 342 funds tracked by Wall St. Rank hold NKTR as of Q4 2018.

  • Krilogy Financial reported no remaining Nektar Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Krilogy Financial sold 20 Nektar Therapeutics shares in Q4 2018, an estimated $18K.
  • Krilogy Financial first reported a position in Nektar Therapeutics in Q1 2018 and held it in 2 quarters.
  • Krilogy Financial's Nektar Therapeutics position peaked at $43K in Q1 2018.
  • 342 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2018.

Based on Krilogy Financial's 13F filing for Q4 2018, filed 14 Feb 2019.